BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 6,500,000 shares of the Company’s common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 6,500,000 shares of common stock at a combined purchase price of $1.00 per share of common stock (or common stock equivalent) and associated warrant in a registered direct offering. The warrants have an exercise price of $1.00 per share, will be exercisable commencing six months following issuance, and will have a term of exercise equal to five years following the initial exercise date.
BlogofInnovation.com
DALLAS, TX- (NewMediaWire) - April 27, 2024 — At an event today featuring the NFL’s Smart Heart Sports Coalition, Buffalo…
Japan Int’l Food & Beverage Expo (JFEX) is gearing up to host an unprecedented gathering of over 900 exhibitors and…
The Synaptic Surgical platform empowers customers to visualize and bring to life cutting-edge OR design and technology Synaptic Surgical (ISIN:…
SPRING, Texas, April 26, 2024 (SEND2PRESS NEWSWIRE) — Houston, we don’t have a foot care problem — now that Modern…
BISMARK, N.D., and MOUNTAIN VIEW, Calif., April 26, 2024 (SEND2PRESS NEWSWIRE) — Imagine notarizing documents from the comfort of your…
IRVINE, Calif., April 26, 2024 (SEND2PRESS NEWSWIRE) — Informative Research, a leading technology platform that delivers data-driven solutions to the lending…
